Pharmaceuticals
Helix BioPharma Reports Reduced Loss, Strengthens Cash Position Amid Strategic Financing
Helix BioPharma Corp. reported a narrowed net loss for the three- and nine-month periods ended April 30, 2026, and a significant cash increase to $2.84 million, driven by a private placement that supports near-term operations and preparations for a U.S. exchange listing.
Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026, Highlighting Immunology Pipeline
Tonix Pharmaceuticals will participate in BTIG Infectious Disease Day 2026, showcasing its immunology programs including a Lyme disease prophylaxis candidate, underscoring its expansion beyond CNS treatments.
Helix BioPharma Reports Reduced Losses, Secures $3.67M Financing to Extend Runway
Helix BioPharma Corp. announced narrower net losses for the nine months ended April 30, 2026, and raised $3.67 million through convertible debentures, strengthening its cash position to approximately twelve months of operating runway while advancing preparations for a U.S. exchange listing.
SureNano Science Accelerates Development of Obesity Drug GEP-44, Initiates FDA-Aligned Preclinical Studies
SureNano Science has begun GLP toxicology and pharmacology studies for its lead drug candidate GEP-44, targeting obesity and type 2 diabetes, marking a crucial step toward clinical trials and FDA approval.
Helus Pharma CMO to Speak at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma's Chief Medical Officer will present at a key industry conference, highlighting the company's progress in developing novel treatments for depression and anxiety.
New Book ‘Weight Loss Decoded’ Seeks to Clarify GLP-1 Medication Confusion
Sharon Polsky’s new book aims to provide clear, science-based information about GLP-1 weight loss medications, addressing common questions and misconceptions.
Watchdog Warns Psychiatry May Thwart Federal Antidepressant Deprescribing Plan
The Citizens Commission on Human Rights warns that psychiatry's history of downplaying drug risks could undermine HHS's May 2026 plan to address overprescribing and support safe antidepressant deprescribing.
Onco-Innovations Advances Manufacturing Process for Cancer Drug Candidate ONC010
Onco-Innovations Limited has initiated process development and scale-up for ONC010's active ingredient, a key step toward regulatory studies and clinical trials.
Optimi Health Completes First Psilocybin Export to UK for Phase 2 Trial
Optimi Health Corp. has exported naturally derived psilocybin to the UK for a planned Phase 2 clinical trial, marking a milestone in international psychedelic drug distribution.
Earth Science Tech Reports Fiscal 2026 Growth and Debt-Free Expansion Across Health Subsidiaries
Earth Science Tech highlighted fiscal 2026 achievements including expansion of Mister Meds, turnaround of DOConsultation and Villas Health, and revenue growth at Peaks surpassing $2 million, all without adding debt, signaling strong financial discipline and strategic progress.
Voyageur Pharmaceuticals Submits Permit Application for Barite Project, Aiming to Become North American Supplier of Pharmaceutical Barium Contrast Agents
Voyageur Pharmaceuticals has submitted a multi-year exploration permit application for its Frances Creek barite project in British Columbia, which could position the company as a secure North American source of pharmaceutical-grade barium contrast products.
Carmed Pharmaceuticals Publishes Second Peer-Reviewed Study of Its Carvacrol-Based Formulations
Carmed Pharmaceuticals highlights a new peer-reviewed study on its formulations Vacrol® and S-Mix® in the journal Antioxidants, underscoring its commitment to scientific research as it expands into the U.S. market.
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies
Aptevo Therapeutics and Niowave Inc. have formed a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, combining Aptevo's targeting platforms with Niowave's isotope supply capabilities to address a $17 billion market.
Redwood AI's AI-Powered Chemistry Platform Targets Drug Discovery and Defense Markets
Redwood AI is developing a proprietary AI platform for drug discovery and chemical analysis, positioning itself across pharmaceutical, defense, and public safety markets through research collaborations and government-supported initiatives.
CNS Pharmaceuticals Secures Oversubscribed $22.5 Million Financing to Fuel Growth Strategy
CNS Pharmaceuticals highlights its oversubscribed $22.5 million financing and strategic reset in a virtual investor presentation, positioning the company to pursue transformational opportunities and create shareholder value.
Oncotelic Therapeutics to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
Oncotelic Therapeutics will present its proprietary PDAOAI platform at Qdrant Vector Space Day 2026, highlighting how it accelerated two drug candidates from concept to investigational new drug filings in under two years, significantly reducing time and cost.
Tonix Pharmaceuticals Expands TONMYA Coverage to 52 Million Commercial Lives
Tonix Pharmaceuticals announced a coverage agreement with a second major group purchasing organization, expanding access to its fibromyalgia treatment, TONMYA, to approximately 52 million U.S. commercial lives, representing about 29% of commercially insured individuals.
Voyageur Pharmaceuticals Closes $5 Million Private Placement to Advance Barium and Iodine Contrast Products
Voyageur Pharmaceuticals has closed a $5 million private placement, raising funds for FDA licensing of its barium contrast suite and development of its Frances Creek barite project and U.S. iodine project.
HighTide Therapeutics Unveils New Data Supporting HTD1801's Renoprotective Effects at ERA 2026
New findings from HighTide Therapeutics show that its lead candidate HTD1801 protects kidney function by targeting podocyte inflammation and apoptosis, offering potential as a disease-modifying therapy for chronic kidney disease.
Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platform to Improve Cancer Treatment Outcomes
Oncotelic Therapeutics is leveraging its Deciparticle platform and Sapu003 program to enhance drug delivery for existing cancer therapies, addressing key challenges in oncology treatment.
Stonegate Capital Partners Updates Coverage on Cingulate Inc. Following FDA Complete Response Letter
Cingulate Inc. faces a CMC-driven resubmission process for CTx-1301 after FDA issues Complete Response Letter, but strong cash position and intact product thesis suggest timeline rather than viability is the key concern.
Kairos Pharma Expands Oncology Pipeline with Proposed Acquisition of Phase 1-Ready c-MET Inhibitor
Kairos Pharma's mid-year update reveals plans to acquire CL-741, a Phase 1-ready oral c-MET inhibitor, expand clinical trials for ENV-105, and secure over $8 million in non-dilutive funding, signaling significant pipeline growth and potential advancements in cancer treatment.
Quantum BioPharma Builds Diversified Pipeline Targeting Neurological and Wellness Markets
Quantum BioPharma Ltd. advances LUCID-MS for multiple sclerosis and expands into alcohol metabolism with unbuzzd, addressing unmet needs in neurology and wellness.
Oncotelic Therapeutics Expands Sapu003 Phase 1b Program with Global CRO Appointment, Signaling Shift to Multinational Development
Oncotelic Therapeutics and Sapu Nano expand the Phase 1b trial for Sapu003, appointing Global Clinical Trials to lead international execution, marking a transition from an Australia-based study to a multinational strategy.
New Pill Daraxonrasib Shows Promise in Doubling Survival for Pancreatic Cancer Patients
Revolution Medicines' daraxonrasib, targeting the KRAS gene, has reportedly doubled survival in early pancreatic cancer trials, offering cautious hope for a disease with limited treatment options.
Onco-Innovations Achieves Kilogram-Scale Manufacturing Milestone for Lead Cancer Drug Candidate
Onco-Innovations Limited successfully produced nearly a kilogram of the B4 precursor for its ONC010 PNKP inhibitor, advancing toward clinical trials and scalable production.
Lexaria Bioscience to Attend BIO International Convention Amid Record Business Development Interest
Lexaria Bioscience Corp. announces its attendance at the BIO International Convention in San Diego, highlighting a surge in partnership interest for its DehydraTECH drug delivery platform, which could lead to significant collaborations with pharmaceutical giants and biotech firms.
GeoVax CEO Sees Renewed Strategic Interest in Vaccine Platforms as Industry Shifts Toward Health Security
GeoVax Labs CEO David Dodd comments on recent pharmaceutical acquisitions, highlighting a strategic shift toward vaccine innovation and health security amid rising global infectious disease threats.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Lucid-MS and Commercial Product unbuzzd™
Quantum BioPharma's lead drug Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its alcohol metabolism product unbuzzd™ generates royalty revenue.
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities in BioMedWire Podcast
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on The BioMedWire Podcast, where co-founder Anthony Durkacz discussed the company's lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd, emphasizing upcoming Phase 2 trials and revenue potential.